Earnings call transcript: Carlsmed's Q2 2025 revenue surges, stock rises

Carlsmed Inc., a personalized spine surgery medical technology company, reported robust Q2 2025 revenue of $12.1 million, marking a 99% year-over-year increase, primarily driven by the adoption of its Aprivo technology platform. Despite a GAAP net loss of $6.8 million and a slight gross margin decrease to 73.4%, the company issued full-year 2025 revenue guidance of $45.5-$47.5 million, projecting 67-75% growth, bolstered by enhanced CMS reimbursement for its devices and plans for a 2026 cervical platform launch. The stock responded positively, gaining 1.87% in aftermarket trading, reflecting investor confidence in its growth trajectory, market expansion, and continued innovation in AI-integrated surgical solutions.

Analysis

Carlsmed Inc. (CARL) reported a highly robust Q2 2025, its first as a public company, with revenue surging 99% year-over-year to $12.1 million. This growth is directly attributed to the accelerating adoption of its Aprivo personalized spine surgery platform, evidenced by a 72% YoY increase in surgeon users to 199. The company's market position is strengthened by compelling clinical data suggesting an 82.6% reduction in reoperation rates and, critically, by recent favorable CMS reimbursement decisions that enhance hospital payments for its procedures. Management has issued strong full-year 2025 revenue guidance of $45.5 million to $47.5 million, representing 67-75% annual growth and signaling confidence in sustained momentum. This optimistic outlook is supported by a fortified balance sheet, with $33.5 million in cash supplemented by $100.5 million in gross proceeds from its July IPO, providing a multi-year runway for strategic execution. However, investors should note the accompanying challenges of a growth-stage company, including a slight gross margin contraction to 73.4% from 75% due to production expedite fees, and a GAAP net loss of $6.8 million driven by increased spending on R&D and commercial expansion. The company's long-term strategy hinges on continued innovation, including AI integration for scalability and a planned 2026 commercial launch of its cervical platform, which will significantly expand its addressable market.

Key Decisions for Investors

• Given the 99% year-over-year revenue growth and strong full-year guidance, investors should evaluate whether the company's current valuation fully captures its market penetration potential within the $13 billion lumbar spine market and its expansion into the cervical segment.
• Closely monitor key execution metrics such as surgeon adoption rates and utilization trends, as management has confirmed these are the primary drivers of future revenue, alongside gross margin performance to see if the recent dip to 73.4% is temporary or indicative of pricing pressure.
• Despite the strong top-line performance, the persistent GAAP net loss of $6.8 million requires careful assessment of the cash burn rate relative to the company's substantial post-IPO cash position to gauge its runway to profitability.
• Future catalysts to watch for include progress updates on the 2026 cervical platform launch and new reimbursement approvals, which could serve as significant de-risking events and further validate the long-term investment thesis.